Last reviewed · How we verify
Coniel — Competitive Intelligence Brief
marketed
benidipine
Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel
Hematology
Small molecule
Live · refreshed every 30 min
Target snapshot
Coniel (BENIDIPINE).
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Coniel TARGET | BENIDIPINE | marketed | benidipine | Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel | ||
| Cinalong | CILNIDIPINE | phase 3 | cilnidipine | Voltage-dependent N-type calcium channel subunit alpha-1B, Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (benidipine class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Coniel CI watch — RSS
- Coniel CI watch — Atom
- Coniel CI watch — JSON
- Coniel alone — RSS
- Whole benidipine class — RSS
Cite this brief
Drug Landscape (2026). Coniel — Competitive Intelligence Brief. https://druglandscape.com/ci/benidipine. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab